Novel therapies are changing treatment paradigms in metastatic prostate cancer

Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose polymerase (PARP) inhibitors for patients with mCRPC and mutations in DNA damage repair...

Descripción completa

Detalles Bibliográficos
Autores principales: Powers, Eric, Karachaliou, Georgia Sofia, Kao, Chester, Harrison, Michael R., Hoimes, Christopher J., George, Daniel J., Armstrong, Andrew J., Zhang, Tian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594418/
https://www.ncbi.nlm.nih.gov/pubmed/33115529
http://dx.doi.org/10.1186/s13045-020-00978-z
Descripción
Sumario:Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose polymerase (PARP) inhibitors for patients with mCRPC and mutations in DNA damage repair genes has added to the treatment armamentarium and improved personalized treatments for prostate cancer. Other promising therapeutic agents currently in clinical development include the radiotherapeutic 177-lutetium-prostate-specific membrane antigen (PSMA)-617 targeting PSMA-expressing prostate cancer and combinations of immunotherapy with currently effective treatment options for prostate cancer. Herein, we have highlighted the progress in systemic treatments for mCRPC and the promising agents currently in ongoing clinical trials.

Ejemplares similares